Once studied as a miracle compound, now erased from mainstream medicine. Here’s why they abandoned it and why your health depends on knowing the truth.
Most men don’t need pregnenolone supplementation, they need to fix the inputs that dictate its production: circadian alignment, micronutrient sufficiency, nervous system recovery, and toxin removal. Hormone panels often reveal downstream chaos that begins with lifestyle. Pregnenolone is a powerful tool, but the real win is making your body want to produce it.
Pregnenolone is fascinating because it’s upstream of everything. Unlike testosterone replacement, which forces one pathway, pregnenolone feeds the entire steroid cascade: progesterone, DHEA, cortisol, aldosterone, testosterone. The body decides allocation based on stress, light exposure, diet, and sleep. This makes it elegant for restoring balance and messy for clinical trials designed to isolate one outcome.
This piece nails a key reality: drug development isn’t a meritocracy of safety and effectiveness, it’s a monopoly game. If a molecule can’t be patented, there’s no $200M clinical pipeline for it, no matter how promising the data. That’s why compounds like pregnenolone, glycine, and even some off-patent antibiotics get ignored. We don’t have a science problem; we have a business model problem.
Most men don’t need pregnenolone supplementation, they need to fix the inputs that dictate its production: circadian alignment, micronutrient sufficiency, nervous system recovery, and toxin removal. Hormone panels often reveal downstream chaos that begins with lifestyle. Pregnenolone is a powerful tool, but the real win is making your body want to produce it.
Pregnenolone is fascinating because it’s upstream of everything. Unlike testosterone replacement, which forces one pathway, pregnenolone feeds the entire steroid cascade: progesterone, DHEA, cortisol, aldosterone, testosterone. The body decides allocation based on stress, light exposure, diet, and sleep. This makes it elegant for restoring balance and messy for clinical trials designed to isolate one outcome.
This piece nails a key reality: drug development isn’t a meritocracy of safety and effectiveness, it’s a monopoly game. If a molecule can’t be patented, there’s no $200M clinical pipeline for it, no matter how promising the data. That’s why compounds like pregnenolone, glycine, and even some off-patent antibiotics get ignored. We don’t have a science problem; we have a business model problem.
A very worthwhile write-up.
🤝